Optimal age and outcome measures for Alzheimer's disease prevention trials in people with Down syndrome

Abstract

Efficient RCTs of AD preventative treatments can be conducted in the DS population using sensitive outcome measures to monitor early decline. Dose-response models could help tailor future RCTs.